...
首页> 外文期刊>Metabolic engineering >Bioengineered human heparin with anticoagulant activity
【24h】

Bioengineered human heparin with anticoagulant activity

机译:具有抗凝活性的生物工程人肝素

获取原文
获取原文并翻译 | 示例

摘要

Heparin is a carbohydrate anticoagulant used clinically to prevent thrombosis, however impurities can limit its efficacy. Here we report the biosynthesis of heparin-like heparan sulfate via the recombinant expression of human serglycin in human cells. The expressed serglycin was also decorated with chondroitin/dermatan sulfate chains and the relative abundance of these glycosaminoglycan chains changed under different concentrations of glucose in the culture medium. The recombinantly expressed serglycin produced with 25mM glucose present in the culture medium was found to possess anticoagulant activity one-seventh of that of porcine unfractionated heparin, demonstrating that bioengineered human heparin-like heparan sulfate may be a safe next-generation pharmaceutical heparin. Crown Copyright (C) 2016 Published by Elsevier Inc. on behalf of International Metabolic Engineering Society. All rights reserved.
机译:肝素是临床上用于预防血栓形成的碳水化合物抗凝剂,但是杂质会限制其功效。在这里,我们报告通过人类细胞中的人血清甘油糖的重组表达生物合成肝素样硫酸乙酰肝素。表达的血清甘油糖还用软骨素/硫酸皮肤素链修饰,并且在培养基中葡萄糖的不同浓度下,这些糖胺聚糖链的相对丰度发生了变化。发现在培养基中存在25mM葡萄糖时产生的重组表达的Serglycin具有抗凝活性,是猪未分级肝素的抗凝活性的七分之一,表明生物工程化的人肝素样硫酸类肝素硫酸盐可能是安全的下一代药物肝素。 Crown版权所有(C)2016,由Elsevier Inc.代表国际代谢工程学会出版。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号